NCT04062370 is a Phase 4 clinical trial of Ranibizumab in Retinal Vein Occlusion, sponsored by Sun Yat-sen University.

Who is sponsoring NCT04062370?

NCT04062370 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT04062370?

Interventions in NCT04062370: Ranibizumab, laser photocoagulation.

What condition does NCT04062370 study?

NCT04062370 studies Retinal Vein Occlusion, Treatment, Photocoagulation Burn to Retina, Ranibizumab.

Is NCT04062370 still recruiting?

NCT04062370 is currently status unknown. Last updated 20 August 2019.

Last reviewed 2019-08-20 · How we verify

NCT04062370

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion

Status unknown Phase 4 Last updated 20 August 2019

What this trial tests

Phase 4 trial testing Ranibizumab in Retinal Vein Occlusion in 100 participants. Status unknown.

Timeline

1 October 2019

Primary endpoint
31 August 2022

31 August 2022

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	1 October 2019
Primary completion	31 August 2022
Estimated completion	31 August 2022
Sites	1 location across China

Drugs / interventions tested

Ranibizumab — full drug profile →
laser photocoagulation

Conditions studied

Retinal Vein Occlusion — all drugs for Retinal Vein Occlusion →
Treatment — all drugs for Treatment →
Photocoagulation Burn to Retina — all drugs for Photocoagulation Burn to Retina →
Ranibizumab — all drugs for Ranibizumab →

Sponsor

Sun Yat-sen University

Who can join

18 and older, any sex, with Retinal Vein Occlusion or Treatment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Retinal vein occlusion (RVO) may lead to series of complications including retinal ischemia, macular edema (ME) and induce vision impairment. Intravitreal injection of Ranibizumab (0.5mg) has been proved to be a safe and effective method for the treatment of RVO-ME. In this study, different treatment regimens of Ranibizumab is applied and the effects is observed at 1-6 months to explore the best regimen for RVO. After 6 months, anti-VEGF therapy and/or laser photocoagulation is used to explore whether laser photocoagulation can maintain the therapeutic effect of Ranibizumab or reduce the injection number.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Ranibizumab

Trials testing the same drug.

NCT06847542 — A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD · Phase 3 · recruiting
NCT06957080 — A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME · Phase 2, PHASE3 · active not recruiting
NCT06176352 — A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Path · Phase 3 · active not recruiting
NCT05126966 — A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Afl · Phase 3 · withdrawn
NCT05480293 — This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab · Phase 3 · unknown

Other recruiting trials for Retinal Vein Occlusion

Currently open trials in the same condition.

NCT07002372 — Effect of Video Viewing on Intravitreal Injection Experience · NA · recruiting
NCT06439576 — Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Relat · recruiting
NCT07106268 — Aqueous Humor Proteome in Retinal Vein Occlusion With Macular Edema · active not recruiting
NCT05476926 — A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products · active not recruiting
NCT04505618 — Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease · NA · recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04062370 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 20 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04062370.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing